- Home
- ACB vs GALT Comparison
ACB vs GALT Comparison
Compare ACB & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | GALT |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 203.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACB | GALT |
|---|---|---|
| Price | $4.06 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.1M | 402.0K |
| Earning Date | 02-04-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $263,570,704.00 | N/A |
| Revenue This Year | $11.82 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.89 | N/A |
| 52 Week Low | $3.42 | $1.12 |
| 52 Week High | $6.91 | $7.13 |
Technical Indicators
Market Signals| Indicator | ACB | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 43.63 |
| Support Level | $3.88 | $2.76 |
| Resistance Level | $4.47 | $3.56 |
| Average True Range (ATR) | 0.14 | 0.22 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 29.75 | 60.00 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.